Search research articles
Contact Us
Filters
Showing results (131-140 of 171) with videos related to
Page
of 18
Sort By:
Cancer
|
November 24, 2020
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma
Neeta Somaiah, Brian Andrew Van Tine, Amy E Wahlquist, et al.
Cancer Medicine
|
August 11, 2022
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
Steven Attia, Vanessa Bolejack, Kristen N Ganjoo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 19, 2021
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
Robin L Jones, César Serrano, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
Sant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2021
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Florence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Anticancer Research
|
March 27, 2026
Analysis of Clinical Benefit Using DNG64-<i>CAR-V</i> Chimeric Tumor Targeted Amphotropic RNA Vector in <i>CCNG1</i> Expressing Cancers
Sant P Chawla, Samantha Jeffrey, Skyler S Pang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2022
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
James Nguyen, Naoko Takebe, Shivaani Kummar, et al.
Future Oncology (London, England)
|
February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma
Gregory M Cote, Sant P Chawla, George Demetri, et al.
Biochemical and Biophysical Research Communications
|
January 21, 2019
Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model
Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 15, 2019
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model
Kentaro Miyake, Takashi Higuchi, Hiromichi Oshiro, et al.
Page
of 18
Search research articles
Search
Showing results (131-140 of 171) with videos related to
Sort By:
Page
of 18
Cancer
|
November 24, 2020
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma
Neeta Somaiah, Brian Andrew Van Tine, Amy E Wahlquist, et al.
Cancer Medicine
|
August 11, 2022
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
Steven Attia, Vanessa Bolejack, Kristen N Ganjoo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 19, 2021
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
Robin L Jones, César Serrano, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
Sant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2021
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Florence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Anticancer Research
|
March 27, 2026
Analysis of Clinical Benefit Using DNG64-<i>CAR-V</i> Chimeric Tumor Targeted Amphotropic RNA Vector in <i>CCNG1</i> Expressing Cancers
Sant P Chawla, Samantha Jeffrey, Skyler S Pang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2022
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
James Nguyen, Naoko Takebe, Shivaani Kummar, et al.
Future Oncology (London, England)
|
February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma
Gregory M Cote, Sant P Chawla, George Demetri, et al.
Biochemical and Biophysical Research Communications
|
January 21, 2019
Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model
Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 15, 2019
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model
Kentaro Miyake, Takashi Higuchi, Hiromichi Oshiro, et al.
Page
of 18